The increased popularity and ubiquitous use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of diabetes, heart failure, and obesity has led to significant concern for increased risk for perioperative aspiration and regurgitation events, given their most notable side effect of delayed gastric emptying which increases gastric contents [1,2,3,4,5,6,7,8,9,10]. Here, GLP1R is linked to obesity disorder.